CN103467376A - New method for preparation of meptazinol hydrochloride critical impurity - Google Patents

New method for preparation of meptazinol hydrochloride critical impurity Download PDF

Info

Publication number
CN103467376A
CN103467376A CN2013103597715A CN201310359771A CN103467376A CN 103467376 A CN103467376 A CN 103467376A CN 2013103597715 A CN2013103597715 A CN 2013103597715A CN 201310359771 A CN201310359771 A CN 201310359771A CN 103467376 A CN103467376 A CN 103467376A
Authority
CN
China
Prior art keywords
compound
iii
haloalkane
reaction
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013103597715A
Other languages
Chinese (zh)
Inventor
王进敏
赵国磊
马苏峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING WANQUAN SUNSHINE MEDICAL TECHNOLOGY Co Ltd
Original Assignee
BEIJING WANQUAN SUNSHINE MEDICAL TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING WANQUAN SUNSHINE MEDICAL TECHNOLOGY Co Ltd filed Critical BEIJING WANQUAN SUNSHINE MEDICAL TECHNOLOGY Co Ltd
Priority to CN2013103597715A priority Critical patent/CN103467376A/en
Publication of CN103467376A publication Critical patent/CN103467376A/en
Pending legal-status Critical Current

Links

Abstract

The invention belongs to the field of pharmaceutical chemistry, relates to a new method for preparation of a meptazinol hydrochloride critical impurity, and particularly relates to the method for preparing the critical impurity 3-(3-ethoxy phenyl)-3-ethyl-1-methyl homopiperidine with 3-(3-hydroxy phenyl)-1-methyl-1H-hexahydroazepine-2-ketone (III) as a starting material and through a two-step reaction. The corresponding characterization of the compound is carried out, and the method is simple in operation.

Description

A kind of novel method for preparing the Wy-22811 critical impurities
Technical field
The present invention relates to the pharmaceutical chemistry field, be specifically related to the novel preparation method of a kind of Wy-22811 critical impurities compound (I).
Figure 301421DEST_PATH_IMAGE001
Background technology
As above structural compounds (I) is a kind of Wy-22811 critical impurities, and its chemistry is by name: 3-(3-ethoxyl phenenyl)-3-ethyl-high piperidines of 1-methyl.
The Wy-22811 chemistry is by name: 3-(3-ethyl-1-methyl isophthalic acid H-six hydrogen azatropylidenes-3-yl) phenolate hydrochlorate.Within 1986, the hydrochloride with racemic modification goes on the market in Britain, and within 1998, British Pharmacopoeia records, and is to use at present the substitute of potent anodyne.Wy-22811 is one of 6 exciting antagonism analgesics of many national recommendations.The Wy-22811 chemical structure is similar to morphine, is the agonist of opium μ acceptor, is also the antagonist of μ acceptor.The anodyne of current clinical use is mostly with habituation. and by contrast, the side effect of Wy-22811 is little, without habituation, is the desirable substitutes such as morphine, dolantin, U-26225A.
Wy-22811 is at present in also not listing of China, China is for a long time to the narcotic analgesic stringent regulations, the kind of current potent anodyne is few, and the alternative medicine Wy-22811 of morphine commonly used and dolantin must have the great market requirement without habituation.This medicine went on the market in 1986, had experienced nearly 30 years in China still not listing, and possible reason: 1. the technique for preparing Wy-22811 is immature; 2. prepare Wy-22811 off quality, special impurity is arranged except not falling.
The contriver is in preparing the Wy-22811 process, obtained a new impurity of not reporting for work at British Pharmacopoeia, this impurity is very obstinate, be difficult to by methods such as recrystallizations it removal, so we has carried out the research work such as separation, preparation, sign to this impurity.
Summary of the invention
The contriver has explored and has developed a method for preparing Wy-22811 critical impurities compound (I).And this compound has been done to corresponding sign, as H-NMR, MS etc., this preparation method is simple to operate.
The present invention take that 3-(3-hydroxy phenyl)-1-methyl isophthalic acid H-six hydrogen azatropylidenes-2-ketone (III) is raw material, synthetic critical impurities (I), compound (III) is first docked with haloalkane and obtains compound (II), then lithium aluminium hydride reduction compound (II) obtains target compound (I), and syntheti c route is as follows:
Figure 601821DEST_PATH_IMAGE002
This reaction scheme mainly carries out in two steps, and the first step is the docking reaction, and the use non-protonic solvent is reaction solvent, adds mineral alkali and haloalkane, and reaction at a certain temperature, by thin-layer chromatography (TLC) monitoring reaction progress.
Non-protonic solvent is chloroform, methylene dichloride, tetrahydrofuran (THF), wherein preferred chloroform.
Haloalkane is monobromethane, monochloroethane, and compound (III) is 1:1 ~ 1:3 with the equivalence ratio of monobromethane or monochloroethane, preferably 1:1.8.Preferred monobromethane.
The temperature of controlling is 20 ℃ of reflux temperatures to reaction system.
Mineral alkali is sodium carbonate, salt of wormwood, sodium hydride, sodium hydroxide, potassium hydroxide.
Second step is reduction process, uses lithium aluminum hydride as going back original reagent.
While preparing compound (I), solvent used is anhydrous tetrahydro furan, anhydrous diethyl ether, preferably anhydrous tetrahydro furan.
The boiling point that temperature of reaction while preparing compound (I) is solvent.
concrete embodiment
Following embodiment is to describe in detail the present invention, but should not be construed as limiting the invention.
Synthesizing of embodiment: 3-(3-the ethoxyl phenenyl)-high piperidines of 3-ethyl-1-methyl-2-ketone.
Embodiment one
Add 6.18 g reaction raw materials (III) in 50 mL there-necked flasks, add methylene dichloride 28 mL, add 3.18 g Na2CO3, add again monobromethane 4.90 g, start reflux, carry out situation by thin-layer chromatography (TLC) monitoring reaction, react 15 hours, raw material (III) is basic to disappear, stop heating, cooling, suction filtration, make to wash with water reaction solution, the concentrated by rotary evaporation organic phase, obtain slightly yellow solid of white, use ethyl acetate-sherwood oil mixed solvent to process and obtain white solid, this solid is placed in to dry 4 hours of 40 ℃ of air dry ovens to constant weight, be weighed as 5.85g, yield 85%, MS:276 [M+H]+.
Embodiment two
Add 6.18 g reaction raw materials (III) in 50 mL there-necked flasks, add trichloromethane 22 mL, add 3.18 g Na2CO3, add again monobromethane 4.90 g, start reflux, carry out situation by thin-layer chromatography (TLC) monitoring reaction, react 9 hours, raw material (III) is basic to disappear, stop heating, cooling, suction filtration, make to wash with water reaction solution, the concentrated by rotary evaporation organic phase, obtain slightly yellow solid of white, use ethyl acetate-sherwood oil mixed solvent to process and obtain white solid, this solid is placed in to dry 4 hours of 40 ℃ of air dry ovens to constant weight, be weighed as 6.20 g, yield 90%, MS:276 [M+H]+.
Embodiment three
Add 6.18 g reaction raw materials (III) in 50 mL there-necked flasks, add trichloromethane 22 mL, 6.62 g Na2CO3, monochloroethane 3.22 g, 0.25 g KI, start reflux, carry out situation by thin-layer chromatography (TLC) monitoring reaction, react 20 hours, raw material (III) is basic to disappear, stop heating, cooling, suction filtration, make to wash with water reaction solution, the concentrated by rotary evaporation organic phase, obtain slightly yellow solid of white, use ethyl acetate-sherwood oil mixed solvent to process and obtain white solid, this solid is placed in to dry 4 hours of 40 ℃ of air dry ovens to constant weight, be weighed as 4.95g, yield 72%, MS:276 [M+H]+.
Embodiment: the preparation of impurity 3-(3-ethoxyl phenenyl)-3-ethyl-high piperidines of 1-methyl
Embodiment four
Add anhydrous tetrahydro furan 30 mL in 50 mL there-necked flasks, add lithium aluminum hydride 1.9 g at the temperature of ice bath, after stirring for some time, add again 3-(3-ethoxyl phenenyl)-high piperidines of 3-ethyl-1-methyl-2-ketone (II) 5.5 g in batches, start reflux, carry out situation by thin-layer chromatography (TLC) monitoring reaction, react 5 hours, reaction completes substantially, raw material point disappears, stop heating, cooling, add slowly water in reaction system, destroy unreacted lithium aluminum hydride, suction filtration, washing, the filtrate water washing, separatory, dry organic phase concentrated by rotary evaporation obtain oily matter, oily matter passes through column chromatography for separation, obtain colorless oil, in 40 ℃ of drying under reduced pressure to constant weight, be 3.6 g, yield 69%, 1H-NMR (CDCl3) δ 0.58 (t, 3H), 1.40 (t, 3H), 1.54 (q, 2H), 1.61-1.75 (m, 5H), 2.13 (q, 1H), 2.38 (s, 3H), 2.42-2.59 (m, 3H), 2.83 (s, 1H), 4.02 (q, 2H), 6.68 (d, 1H), 6.68-6.89 (m, 2H), 7.2 (t, 1H). MS:262 [M+H]+.
Embodiment five
Add anhydrous diethyl ether 30 mL in 50 mL there-necked flasks, add lithium aluminum hydride 1.9 g at the temperature of ice bath, after stirring for some time, add again 3-(3-ethoxyl phenenyl)-high piperidines of 3-ethyl-1-methyl-2-ketone (II) 5.5 g in batches, start reflux, carry out situation by thin-layer chromatography (TLC) monitoring reaction, react 12 hours, reaction completes substantially, raw material point disappears, stop heating, cooling, add slowly water in reaction system, destroy unreacted lithium aluminum hydride, suction filtration, washing, the filtrate water washing, separatory, dry organic phase concentrated by rotary evaporation obtain oily matter, oily matter passes through column chromatography for separation, obtain colorless oil, in 40 ℃ of drying under reduced pressure to constant weight, be 3.4 g, yield 65%, 1H-NMR (CDCl3) δ 0.58 (t, 3H), 1.40 (t, 3H), 1.54 (q, 2H), 1.61-1.75 (m, 5H), 2.13 (q, 1H), 2.38 (s, 3H), 2.42-2.59 (m, 3H), 2.83 (s, 1H), 4.02 (q, 2H), 6.68 (d, 1H), 6.68-6.89 (m, 2H), 7.2 (t, 1H). MS:262 [M+H]+. ?

Claims (9)

1. the syntheti c route of a Wy-22811 critical impurities (I) is as follows, it is characterized in that using compound (III) is raw material, under the effect of mineral alkali, compound (III) docks in non-protonic solvent with haloalkane and prepares compound (II), in compound (II) prepares the process of compound (I), use tetrahydrofuran (THF) or ether to make solvent, lithium aluminum hydride obtains target compound (I) for going back original reagent
2. according to the method for claim 1, haloalkane is monobromethane, monochloroethane.
3. according to the method for claim 1, the mineral alkali while preparing compound (II) is sodium carbonate, salt of wormwood, sodium hydride, sodium hydroxide, potassium hydroxide.
4. according to the method for claim 1, non-protonic solvent is chloroform, methylene dichloride, tetrahydrofuran (THF).
5. according to the method for claim 4, non-protonic solvent is chloroform.
6. according to the method for claim 1, compound (III) is 1:1 ~ 1:3 with the equivalence ratio of haloalkane.
7. according to the method for claim 6, compound (III) is 1:1.8 with the equivalence ratio of haloalkane.
8. according to the method for claim 1, the temperature of reaction for preparing compound (II) is 20 ℃ of reflux temperatures to reaction system.
9. according to the method for claim 1, using anhydrous tetrahydro furan while preparing compound (I) is solvent.
CN2013103597715A 2013-08-19 2013-08-19 New method for preparation of meptazinol hydrochloride critical impurity Pending CN103467376A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2013103597715A CN103467376A (en) 2013-08-19 2013-08-19 New method for preparation of meptazinol hydrochloride critical impurity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2013103597715A CN103467376A (en) 2013-08-19 2013-08-19 New method for preparation of meptazinol hydrochloride critical impurity

Publications (1)

Publication Number Publication Date
CN103467376A true CN103467376A (en) 2013-12-25

Family

ID=49792457

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2013103597715A Pending CN103467376A (en) 2013-08-19 2013-08-19 New method for preparation of meptazinol hydrochloride critical impurity

Country Status (1)

Country Link
CN (1) CN103467376A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1285025A (en) * 1968-08-16 1972-08-09 Wyeth John & Brother Ltd Hexahydroazepines
CN1562975A (en) * 2004-04-07 2005-01-12 复旦大学 Method for preparing 1-methyl-3-ethyl-3-(3-hydroxy phenyl)-hexa hydrogen-1 H azepin hydrochloride
CN102321022A (en) * 2011-06-03 2012-01-18 北京双鹤药业股份有限公司 Method for preparing meptazinol and analogs thereof
CN102503781A (en) * 2011-09-28 2012-06-20 河北工业大学 Method for preparing phenol ether through reaction of phenolic compound and halogenated hydrocarbon

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1285025A (en) * 1968-08-16 1972-08-09 Wyeth John & Brother Ltd Hexahydroazepines
CN1562975A (en) * 2004-04-07 2005-01-12 复旦大学 Method for preparing 1-methyl-3-ethyl-3-(3-hydroxy phenyl)-hexa hydrogen-1 H azepin hydrochloride
CN102321022A (en) * 2011-06-03 2012-01-18 北京双鹤药业股份有限公司 Method for preparing meptazinol and analogs thereof
CN102503781A (en) * 2011-09-28 2012-06-20 河北工业大学 Method for preparing phenol ether through reaction of phenolic compound and halogenated hydrocarbon

Similar Documents

Publication Publication Date Title
WO2016026380A1 (en) Method for preparing idelalisib
AU2011281421A1 (en) Process for preparing aminobenzoylbenzofuran derivatives
CN103102307A (en) Method for synthesizing tolfenpyrad
CN102600892B (en) Application of triarylimidazole compound serving as catalyst in electroorganic synthesis
CN106279104B (en) A kind of process modification method preparing amber love song Ge Lieting
CN104447620B (en) 1-[3-[3-(4-chlorphenyl) propoxyl group] propyl group] preparation method of-piperidine hydrochlorate
CN103864674A (en) Method for preparing (R)-3-amino piperidine hydrochloride
JP5585822B2 (en) Method for producing optically active nipecotic acid derivative
CN104193694B (en) A kind of method preparing Parecoxib Sodium intermediate
CN103833717B (en) A kind of synthetic method of nebivolol hydrochloride
KR101810515B1 (en) 4-benzyl-1-phenethyl-piperazine-2,6-dione preparation method, and intermediate and preparation method thereof
CN103467376A (en) New method for preparation of meptazinol hydrochloride critical impurity
CN103626791B (en) A kind of method of synthesizing 3-amino-4-fluorobenzoic boric acid
CN104072495B (en) The preparation method of natural product alkaloid A aptamine
CN103467377A (en) Preparation method of meptazinol hydrochloride critical impurity
CN102850244A (en) Preparation method for 3-(3-phenylsulfamoyl-phenyl)-acrylic acid
CN108299224A (en) A kind of preparation method of N- acetyl group -1- cyclohexylethylamines
CN104610215A (en) Preparation method of nebivolol intermediates and preparation method of nebivolol
CN104530060B (en) A kind of preparation method of Bio key intermediate (3aS, 6aR)-lactone
CN104557918A (en) Method for preparing benzisoxazole antipsychotic drug risperidone
CN104974059A (en) Rivaroxaban intermediate and preparation method thereof
CN103709089B (en) One prepares the method for 3-(4 '-chlorobutyl)-5-cyanoindole
CN104098556A (en) Novel synthetic process for rivaroxaban
CN103755657A (en) Preparation method of rivaroxaban intermediate
CN103864771A (en) Rivaroxaban preparation method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131225